Description

10x Genomics: Product Utilization & Growth of Spatial & Single Cell Technologies & Key Growth Levers!

10x Genomics faced a challenging first quarter of 2025, marked by both positive developments and significant uncertainties. The company reported total revenue of $155 million, with a substantial boost from a settlement with Vizgen included in this figure. Excluding the settlement’s contribution, revenue stood at $138 million, reflecting a 2% year-over-year decline. This performance was primarily due to a sharp decrease in instrument revenues that was somewhat offset by robust growth in consumable sales.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!